Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Single-Arm Lorlatinib in ALK-Positive NSCLC After One Prior Second-Generation ALK TKI
2019-002504-41Phase 4Completed
- Sponsor
- Pfizer
- Start
- May 2020
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of lorlatinib in non-small cell lung cancer (NSCLC), sponsored by Pfizer. Primary endpoints: Confirmed Objective Tumor Response (Overall Response Rate) and Intracranial Objective Response Rate. Started May 2020; status: completed.
02
Drugs
lorlatinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2019-002504-41.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-002504-41.